Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

European Journal of Heart Failure

Volumn 13, Issue 10, 2011, Pages 1087-1095

  Collier, Patrick ^a,b   Watson, Chris J ^a   Voon, Victor ^a,b   Phelan, Dermot ^a,b   Jan, Aftab ^a,b   Mak, George ^a,b   Martos, Ramon ^a,b   Baugh, John A ^a   Ledwidge, Mark T ^b   McDonald, Kenneth M ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Biomarkers; Fibrosis; Heart failure; Hypertension; Inflammation

Indexed keywords

AMINO TERMINAL TYPE 1 COLLAGEN PROPEPTIDE; AMINO TERMINAL TYPE 3 COLLAGEN PROPEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TYPE 1 COLLAGEN PROPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT ATRIUM VOLUME INDEX; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART VOLUME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CROSS-SECTIONAL STUDIES; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; HYPERTENSION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80053246717     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr079     Document Type: Article

References (30)

1. Najafi F, Jamrozik K, Dobson AJ. Understanding the epidemic of heart failure: a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009; 11:472-479.
2. Diez J, Laviades C, Monreal I, Gil MJ, Panizo A, Pardo J. Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Am J Cardiol 1995;76: 14D- D17.
3. Navarro-Gonzalez JF, Mora C, Muros M, Jarque A, Herrera H, Garcia J. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens 2008;26:2168-2175.
4. Futai R, Ito T, Kawanishi Y, Terasaki F, Kitaura Y. Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. Heart Vessels 2009;24:294-300.
5. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004;43:739-745.
6. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010;56:225-231.
7. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004;43:716-719.
8. OHanlon R, OShea P, Ledwidge M, OLoughlin C, Lange S, Conlon C, Phelan D, Cunningham S, McDonald K. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:50-55.
9. Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Diez J, Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007;25:1958-1966.
10. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
11. Plaksej R, Kosmala W, Frantz S, Herrmann S, Niemann M, Stork S, Wachter R, Angermann CE, Ertl G, Bijnens B, Weidemann F. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 2009;27:2483-2491.
12. Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010;55:1418-1424.
13. Jaubert MP, Armero S, Bonello L, Nicoud A, Sbragia P, Paganelli F, Arques S. Predictors of B-type natriuretic peptide and left atrial volume index in patients with preserved left ventricular systolic function: an echocardiographic-catheterization study. Arch Cardiovasc Dis 2010;103:3-9.
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
15. Martos R, Baugh J, Ledwidge M, OLoughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 2009;11:191-197.
16. Mak GJ, Ledwidge MT,Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, McDonald KM. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674-1682.
17. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
18. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002;8:390-398.
19. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010;55:2129-2137.
20. Leibowitz D, Planer D, Ben-Ivgi F, Weiss AT, Bursztyn M. Tumor necrosis factor and interleukin-6 levels in hypertensive patients with and without left ventricular hypertrophy. Blood Press 2005;14:21-24.
21. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2009;2:303-310.
22. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004;110:1263-1268.
23. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J, Fritzenwanger M, Figulla HR, Brehm BR. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009;11:1057-1062.
24. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003;21:1627-1630.
25. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 2007;282:37585-37596.
26. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141.
27. Eddy AA, Kim H, Lopez-Guisa J, Oda T, Soloway PD. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 2000; 58:618-628.
28. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035.
29. Vailati Mdo C, Rocha NS, Matsubara LS, Padovani CR, Schwartz DS, Matsubara BB. Protective effects of carvedilol on systemic vascular damage induced by angiotensin II: organ-specific effects independent of antihypertensive effects. Med Sci Monit 2010;16:BR6-BR10.
30. Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000;2:451-456